Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT06148181 · ClinicalTrials.gov registry record · Phase 1
A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants
A Phase 1 study, sponsored by AbbVie.
- Completed
- Registry status
- Phase 1
- Development phase
- 41
- Enrollment target
NCT06148181 is a Phase 1 study that has completed, run by AbbVie. The registered enrollment target is 41 participants.
The verdict
NCT06148181, a Phase 1 study, has completed, sponsored by AbbVie.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 41 participants
- Enrollment target
Study Summary
The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.
Interventions
- DRUG ABBV-141
- DRUG Placebo for ABBV-141
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 41 participants |
| Start Date | 2024-01-29 |
| Est. Completion | 2024-12-30 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT06148181
The ClinicalTrials.gov registry entry for NCT06148181 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 41 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is AbbVie, which has 526 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which ABBV-141 is the first listed.
NCT06148181 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT06148181 about?
NCT06148181 is a clinical study titled "A Study to Evaluate Adverse Events and How Single Ascending Doses of ABBV-141 Move Through the Body of Healthy Adult Western and Asian Participants". The purpose of this study is to assess the safety, tolerability, pharmacokinetics (PK) and immunogenicity after single ascending doses (SAD) of ABBV-141 in healthy adult Western and Asian participants.
What is the current status of trial NCT06148181?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 41 participants. The study started on 2024-01-29. Estimated completion is 2024-12-30.
What interventions are being tested in trial NCT06148181?
The interventions under investigation include: ABBV-141 (DRUG), Placebo for ABBV-141 (DRUG).
Who is sponsoring clinical trial NCT06148181?
This trial is sponsored by AbbVie, which has 526 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.